These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32236392)

  • 1. Editorial: Alzheimer's Disease Drug Development Pipeline 2020.
    Sabbagh MN
    J Prev Alzheimers Dis; 2020; 7(2):66-67. PubMed ID: 32236392
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.
    Kramer LD
    J Prev Alzheimers Dis; 2020; 7(3):142-143. PubMed ID: 32463064
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Next-Generation Alzheimer's Therapeutics: Leveraging Deep Biology.
    Longo FM; Massa SM
    J Prev Alzheimers Dis; 2020; 7(3):138-139. PubMed ID: 32463062
    [No Abstract]   [Full Text] [Related]  

  • 5. Accelerating Alzheimer's disease drug innovations from the research pipeline to patients.
    Goldman DP; Fillit H; Neumann P
    Alzheimers Dement; 2018 Jun; 14(6):833-836. PubMed ID: 29680407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Approaches to Develop Drug Treatment for Alzheimer's Disease: Targeting Calcium Dysregulation.
    Wei H
    Curr Alzheimer Res; 2020; 17(4):311-312. PubMed ID: 32623998
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.
    Schneider LS
    J Prev Alzheimers Dis; 2020; 7(3):199-200. PubMed ID: 32463075
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting apolipoprotein E for treating Alzheimer's disease.
    Bales KR; Paul SM
    Neurosci Lett; 2019 Sep; 709():134366. PubMed ID: 31336138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Siemers E
    J Prev Alzheimers Dis; 2019; 6(3):180-181. PubMed ID: 31062831
    [No Abstract]   [Full Text] [Related]  

  • 10. New Hope for Alzheimer's Disease.
    Vellas B; Aisen P
    J Prev Alzheimers Dis; 2021; 8(3):238-239. PubMed ID: 34101778
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: Failure After Failure. What Next in AD Drug Development?
    Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):150. PubMed ID: 31062821
    [No Abstract]   [Full Text] [Related]  

  • 12. The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs.
    Cummings J
    J Prev Alzheimers Dis; 2020; 7(4):288-290. PubMed ID: 32920632
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: Multi Target - Directed Ligands in the Treatment of Alzheimer's Disease.
    Soukup O; Korabecny J
    Curr Alzheimer Res; 2019; 16(9):771. PubMed ID: 31729288
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Be open about drug failures to speed up research.
    Alteri E; Guizzaro L
    Nature; 2018 Nov; 563(7731):317-319. PubMed ID: 30425369
    [No Abstract]   [Full Text] [Related]  

  • 16. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.
    Vellas B; Bain LJ; Touchon J; Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):198-203. PubMed ID: 31062835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach.
    Cummings JL
    Dement Geriatr Cogn Disord; 2020; 49(1):22-37. PubMed ID: 32512572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of early stages of Alzheimer's disease: New guidelines are in the pipeline].
    Winblad B; Kivipelto M; Andersen P; Johansson G; Andreasen N
    Lakartidningen; 2013 Sep 11-17; 110(37):1613. PubMed ID: 24163935
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: The dawn of a new era of Alzheimer's research and drug development.
    Hara Y; Fillit HM
    J Prev Alzheimers Dis; 2022; 9(3):385-386. PubMed ID: 35841237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.